InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Schorno Dean L, Chief Financial Officer. Officer active across 1 company, notably RIGEL PHARMACEUTICALS INC. In total, 11 filings have been published. Split: 0 buy · 3 sells. Total volume traded: €55k. History available since 24 January 2022. The latest transaction was filed on 17 February 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Schorno Dean L
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations11 total
20,636 shares0Common StockSEC:0000905148-26-000952:0
3,546 shares@ US$34.6228.7% of flowCommon StockSEC:0000905148-26-000678:0
5,488 shares@ US$36.0146.5% of flowCommon StockSEC:0000905148-26-000497:0
1,987 shares@ US$20.0038.1% of flowCommon StockSEC:0000905148-25-004492:0
2,036 shares@ US$20.92174.7% of flowCommon StockSEC:0000905148-25-000413:0
19,717 shares0Common StockSEC:0000905148-25-000300:0
5,601 shares@ US$1.129610.5% of flowCommon StockSEC:0000905148-24-000446:0
209,000 shares0Common StockSEC:0000905148-24-000306:0
5,389 shares@ US$1.660114.7% of flowCommon StockSEC:0001140361-23-004732:0
63,000 shares0Common StockSEC:0001140361-23-003441:0
50,000 shares0Common StockSEC:0001567619-22-001782:0
11 of 11 declarations
About Schorno Dean L
Dean L. Schorno is the Executive Vice President and Chief Financial Officer of Rigel Pharmaceuticals Inc. In this role, he oversees the company's financial operations, including cash management and financial reporting. With expertise in the pharmaceutical sector, he contributes to the financial strategy of Rigel Pharmaceuticals, which develops treatments for serious diseases.
